SAFETY OF ERADICATION THERAPY OF HELICOBACTER PYLORI INFECTION: SYSTEMATIZATION OF LITERATURE DATA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article systematizes literature data on the safety of eradication therapy (ET) of Helicobacter pylori infection. Data on the individual safety profile and tolerability of antibacterial drugs included in the ET regimens are presented. It is shown that the risk of development of side effects with the use of ET is 24% on average and varies depending on the specific treatment regimen: triple therapy with clarithromycin (21-24%), triple therapy with metronidazole (30%), bismuth-containing quadrupletherapy (23%), quadrupletherapy therapy without bismuth preparations (24%), sequential therapy (22%), triple therapy with levofloxacin (15-27%), hybrid therapy (26-32.9%). The factors that increase the risk of side effects include the duration of the course of therapy, incorrect dosage of drugs, the presence of concomitant liver pathology, including cirrhosis. A significant reduction in the incidence of side effects associated with ET can be achieved only with the use of adjuvant therapy with the probiotics.

Full Text

Restricted Access

About the authors

D. N Andreev

FSBEI HE “Moscow State Medical Stomatological University n.a. A.I. Evdokimov" of RMH

Email: mit8@mail.ru
PhD, Teaching Assistant at the Department of Propaedeutics of Internal Diseases and Gastroenterology

I. V Mayev

FSBEI HE “Moscow State Medical Stomatological University n.a. A.I. Evdokimov" of RMH

A. A Samsonov

FSBEI HE “Moscow State Medical Stomatological University n.a. A.I. Evdokimov" of RMH

E. G Lobanova

FSBEI HE “Moscow State Medical Stomatological University n.a. A.I. Evdokimov" of RMH

E. V Partsvania-Vinogradova

FSBEI HE “Moscow State Medical Stomatological University n.a. A.I. Evdokimov" of RMH

References

  1. Маев И.В., Самсонов А.А., Андреев Д.Н. Инфекция Helicobacter pylori. М., 2016.
  2. Morgan D.R., Crowe S.E. Helicobacter pylori infection. In.: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. Edited by M. Feldman, L.S. Friedman, L.J. Brandt. 10th ed. 2015.
  3. Malfertheiner P., Link A., Selgrad M. Helicobacter pylori: perspectives and time trends. Nat. Rev. Gastroenterol. Hepatol. 2014;11(10):628-38.
  4. Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. Тер. архив. 2014;3:94-9.
  5. Андреев Д.Н., Дичева Д.Т., Маев И.В. Возможности оптимизации эрадикационной терапии инфекции Helicobacter pylori в современной клинической практике. Тер. архив. 2017;2:76-83.
  6. Maev I.V., Andreev D.N., Kucheryavyi Yu.A., Dicheva D.T. Host factors influencing the eradication rate of Helicobacter pylori. World Applied Sci. J. 2014;30:134-40.
  7. O’Connor J.R, Taneike I., O’Morain C. Improving compliance with Helicobacter pylori eradication therapy: when and how? Therap. Adv. Gastroenterol. 2009;2(5):273-79.
  8. Malfertheiner P., Megraud F., O'Morain C.A., Gisbert J.R., Kuipers E.J., Axon A.T., Bazzoli F., Gasbarrini A., Atherton J., Graham D.Y., Hunt R., Moayyedi P., Rokkas T., Rugge M., Selgrad M., Suerbaum S., Sugano K., El-Omar E.M. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30
  9. Fallone C.A., Chiba N., van Zanten S.V., Fischbach L., Gisbert J.P., Hunt R.H., Jones N.L., Render C., Leontiadis G.I., Moayyedi P., Marshall J.K. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016;151(1):51-69.e14.
  10. Chey W.D., Leontiadis G.I., Howden C.W., Moss S.F. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am. J. Gastroenterol. 2017;112(2):212-39.
  11. Peura D.A. Treatment of Helicobacter pylori infection. In: M.M. Wolfe, ed. Therapy of digestive disorders. Philadelphia: Elsevier, 2006. 277 p.
  12. Hudson N., Brydon W.G., Eastwood M.A., Ferguson A., Palmer K.R. Successful Helicobacter pylori eradication incorporating a one-week antibiotic regimen. Aliment. Pharmacol. Ther. 1995;9(1):47-50.
  13. Sabaté E., ed. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization. 2003.
  14. Li B.Z., Threapleton D.E., Wang J.Y., et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015;351:h4052.
  15. Андреев Д.Н. Эффективность и безопасность эрадикационной терапии инфекции Helicobacter pylori у пациентов с сопутствующим хроническим вирусным гепатитом С. Дисс. канд. мед. наук. М., 2016.
  16. Cunha B.A. Antibiotic side effects. Med. Clin. North. Am. 2001;85(1):149-85.
  17. Cerny A. Side effects and consequences of frequently used antibiotics in clinical practice. Schweiz Med. Wochenschr. 1996;126(13):528-34.
  18. Kullak-Ublick G.A., Andrade R.J., Merz M., End P., Benesic A., Gerbes A.L., Aithal G.P Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut. 2017;66(6): 1154-64.
  19. Andrade R.J., Camargo R., Lucena M.I., González-Grande R. Causality assessment in drug-induced hepatotoxicity. Expert. Opin. Drug. Saf. 2004;3(4):329-44.
  20. Andrade R.J., Tulkens P.M. Hepatic safety of antibiotics used in primary care. J. Antimicrob. Chemother. 2011;66(7):1431-46.
  21. de Abajo F.J., Montero D., Madurga M., Garca Rodriguez L.A. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br. J. Clin. Pharmacol. 2004;58(1):71-80.
  22. Westphal J.F., Vetter D., Brogard J.M. Hepatic side-effects of antibiotics. J. Antimicrob. Chemother. 1994;33(3):387-401.
  23. Бурбелло А.Т. Бабак С.В., Андреев Б.В. и др. Неблагоприятные побочные реакции лекарственных средств (пособиедля врачей). СПб., 2008.
  24. Андреев Д.Н., Маев И.В., Дичева Д.Т., Кучерявый Ю.А. Комплексная оценка безопасности двух режимов эрадикационной терапии инфекции Helicobacter pylori у пациентов с хроническим гепатитом C. Фарматека. 2016;2:19-22.
  25. Андреев Д.Н., Маев И.В., Дичева Д.Т., Кучерявый Ю.А., Парцваниа-Виноградова Е.В. Анализ влияния фиброза печени на эффективность и безопасность антихеликобактерной терапии. Фарматека. 2015;20:69-71.
  26. Андреев Д.Н., Маев И.В., Кучерявый Ю.А., Дичева Д.Т., Парцваниа-Виноградова Е.В. Эффективность и безопасность антихеликобактерной терапии у пациентов с сопутствующим хроническим гепатитом С. Тер. архив. 2016;4:75-81.
  27. Delcò F., Tchambaz L., Schlienger R., Drewe J., Krähenbühl S. Dose adjustment in patients with liver disease. Drug. Saf. 2005;28(6):529-45.
  28. Franz C.C., Hildbrand C., Born C., Egger S., Rätz Bravo A.E., Krähenbühl S. Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations. Eur. J. Clin. Pharmacol. 2013;69(8):1565-73.
  29. Naranjo C.A., Busto U., Mardones R. Adverse drug reactions in liver cirrhosis. European J. Clin. Pharmacol. 1978;13(6):429-34.
  30. Puig I., Baylina M, Sánchez-Delgado J., et al. Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment. J. Antimicrob. Chemother. 2016;71(10):2740-53.
  31. Маев И.В., Андреев Д.Н., Самсонов А.А., Велиев А.М. Современные схемы эрадикационной терапии инфекции Helicobacter pylori: стратегия дифференцированного применения, эффективность и безопасность. Эксперим. и клин. гастроэнтерол. 2017;4(140):103-10.
  32. Song Z.Q., Liu J., Zhou L.Y. Hybrid Therapy Regimen for Helicobacter Pylori Eradication. Chin. Med. J. (Engl). 2016;129(8):992-99.
  33. Hsu P.I., Lin P.C., Graham D.Y. Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis. World J. Gastroenterol. 2015;21(45):12954-62.
  34. Song Z.Q., Zhou L.Y. Hybrid, sequential and concomitant therapies for Helicobacter pylori eradication: A systematic review and meta-analysis. World J. Gastroenterol. 2016;22(19):4766-75.
  35. Szajewska H., Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32(9):1069-79.
  36. Wang Z.H., Gao Q.Y., Fang J.Y. Meta-Analysis of the Efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J. Clin. Gastroenterol. 2013;47(1):25-32.
  37. Lau C.S., Ward A., Chamberlain R.S. Probiotics improve the efficacy of standard triple therapy in the eradication of Helicobacter pylori: a meta analysis. Infect. Drug Resist. 2016;9:275-89.
  38. Lv Z., Wang B., Zhou X., Wang F., Xie Y., Zheng H., Lv N. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A metaanalysis. Exp. Ther. Med. 2015;9(3):707-16.
  39. Feng J.R., Wang F., Qiu X., McFarland L.V., Chen P.F., Zhou R., Liu J., Zhao Q., Li J. Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network metaanalysis. Eur. J. Clin. Pharmacol. 2017 Jul 5. doi: 10.1007/s00228-017-2291-6.
  40. Маев И.В., Андреев Д.Н., Дичева Д.Т., Гончаренко А.Ю. Фармакотерапевтические аспекты применения ингибиторов протонной помпы. Мед. вестник МВД. 2013;3(64):9-14.
  41. Инструкция по медицинскому применению препарата Париет®.
  42. Инструкция по медицинскому применению препарата Нольпаза.
  43. Инструкция по медицинскому применению препарата Нексиум.
  44. Инструкция по медицинскому применению препарата Омез.
  45. Choi H.S., Park D.I., Hwang S.J., Park J.S., Kim H.J., Cho Y.K., Sohn C.I., Jeon W.K., Kim B.I. Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate. Helicobacter. 2007;12(6):638-42.
  46. Chia-Fen Tsai et al. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study. Gastroenterology. 2017;152:134-41.
  47. Lee J.Y., Park K.S. Optimal First-Line Treatment for Helicobacter pylori Infection: Recent Strategies. Gastroenterol. Res. Pract. 2016;2016:9086581.
  48. Desta Z.X., Shin J.G., Flockhart D.A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 2002;41(12):913-58.
  49. Li-Wan-Po A., Girard T., Farndon P., Cooley C., Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br. J. Clin. Pharmacol. 2010;69(3):222-30.
  50. Kuo C.H., Lu C.Y., Shih H.Y., Liu C.J., Wu M.C., Hu H.M., Hsu W.H., Yu F.J., Wu D.C., Kuo F.C. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J. Gastroenterol. 2014;20(43):16029-36.
  51. Заборовский А.В., Маев И.В., Андреев Д.Н., Тарарина Л.А. Плейотропные эффекты рабепразола и их роль в лечении пациентов с кислотозависимыми заболеваниями. Росc. журн. гастроэнтерологии, гепатологии, колопроктологии. 2017;27(3):18-26.
  52. Padol S., Yuan Y., Thabane M., Padol I.T., Hunt R.H. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am. J. Gastroenterol. 2006;101(7):1467-75.
  53. Sakai T., Aoyama N., Kita T., Sakaeda T., Nishiguchi K., Nishitora Y., Hohda T., Sirasaka D., Tamura T., Tanigawara Y., Kasuga M., Okumura K. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm. Res. 2001;18(6):721-27.
  54. Tang H.L., Li Y., Hu Y.F., Xie H.G., Zhai S.D. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS. One. 2013;8:e62162.
  55. McNicholl A.G., Linares P.M., Nyssen O.P., Calvet X., Gisbert J.P Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 2012;36(5):414-25.
  56. Denisenko N.P., Sychev D.A., Sizova Zh.M., Grachev A.V., Velikolug K.A. High frequency of CYP2C19 ultrarapid metabolizers in Russian patients with peptic ulcer. Exp. Clin. Gastroenterol. 2015;(6):11-5.
  57. Ohara T., Goshi S., Taneike I.,Tamura Y., Zhang H.M., Yamamoto T. Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori. Helicobacter. 2001;6(2):125-29.
  58. Zhang Z., Liu Z.Q., Zheng P.Y., Tang F.A., Yang P.C. Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori. World J. Gastroenterol. 2010;16(10):1279-84.
  59. Skoczylas T., Sarosiek I., Sostarich S., et al. Signicant enhancement of gastric mucin content after rabeprazole administration: its potential clinical signicance in acid-related disorders. Dig. Dis. Sci. 2003;48:322-28.
  60. Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Антибиотикорезистентность Helicobacter pylori: от клинического значения до молекулярных механизмов. Леч. врач. 2014;2:34.
  61. Самсонов А.А., Андреев Д.Н., Гречушников В.Б., Айвазова Р.А. Резистентность Helicobacter pylori к компонентам эрадикационной терапии и пути ее преодоления. Фарматека. 2015;2(295):26-30.
  62. Симаненков В.И., Захарова Н.В., Жебрун А.Б., Сварваль А.В., Савилова И.В., Ферман Р.С. Резистентность Helicobacter pylori к антимикробным препаратам по результатам бактериологического тестирования. Леч. врач. 2015;4:91-5.
  63. Калугин А.А., Степченко А.А., Воропаев Е.В., Осипкина О.В., Зятьков А.А. Частота выявления полиморфизма генов Helicobacter pylori, ассоциированных с устойчивостью к кларитромицину. Курский научно-практический вестник «Человек и его здоровье». 2016;3:17-21.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies